Dr. Stephane Gesta’s role is to translate the company’s preclinical discovery programs for IND filing and first in human studies. His vision for healthcare is to bring the right medication to the right patient. Dr Gesta oversees the Discovery and Translational Biology group which focuses on preclinical strategy to communicate a path for clinical development. He leads a team of scientists in oncology, neurology, and in vivo pharmacology, to apply discoveries generated during preclinical studies, to the development of trials and studies in human. He manages several R&D collaborations with strategic academic partners to maximize drug pipeline development. Recently, the work of Dr Gesta’s team in defining drug mechanism of action enabled the development of a clinical plan for first in human studies in oncology. He is an author on more than 30 publications, and an inventor on more than 10 patents.

Dr. Gesta received a master’s degree in Cellular Biology and Physiology from the University Paul Sabatier in Toulouse, France, where he developed a passion for understanding human physiology and pathophysiology at the whole-body, system, organ, cellular, and molecular level, to treat diseases with unmet needs. Dr. Gesta received a Ph.D. in Molecular and Cellular Pharmacology from the University Paul Sabatier, after studying adrenergic receptivity regulating the paracrine function of adipose tissue in obese patients. He completed his postdoctoral training at the Joslin Diabetes Center in Boston where he was a Research Associate Fellow. He also served as an Instructor of Medicine at Harvard Medical School in Boston. Dr. Gesta’s work has been published in top-tier journals and presented at numerous international conferences.